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One challenge to the incorporation of chromosomemicro-
array in the clinical setting is outcome prediction in fetuses
and young babies who have copy-number changes. It’s one
thing to find a copy-number change in a child whose
parents are seeking an explanation for the child’s develop-
mental delays; it is another to find the same change in
a younger sibling or a fetus. Even for well-documented
pathogenic copy-number changes, the reduced penetrance
and variable expression make it hard to explain to families
what the future holds. Rosenfeld et al. used data from clin-
ical samples collected by Signature Genomics over several
years and compared these to more than 20,000 control
samples in order to get penetrance estimates for specific
recurrent copy-number changes. These estimates range
from 10.4% for 15q11.2 deletions to 62.4% for distal
16p11.2 deletions. Although there was no attempt to parse
out different phenotypes in this analysis, these data do
provide one more piece of concrete information for use
in genetic counseling.
Rosenfeld et al. (2012). Genet. Med. Published online
December 20, 2012. 10.1038/gim.2012.164.
Universally Different
Although each mammalian cell has numerous mitochon-
dria, each with its own genome, it is generally believed
that they are identical, at least at birth, in any given indi-
vidual. Not so, say Payne et al.—as determined by ultra-
deep resequencing of mitochondrial genomes in healthy
individuals, heteroplasmy is universal in both blood and
skeletal muscle. This sequence variation is not simply
acquired with age, as might be expected given the rela-
tively high mutation rate for mitochondrial DNA; rather,
the variant sequences are very often shared between
maternally related individuals, suggesting that they are
inherited. If this is true, we might have to rethink the
inheritance of variation in mitochondrial DNA and the
dynamics of these variants with age.
Payne et al. (2013). Hum. Mol. Genet. 22, 384–390.
Even Higher Throughput Sequencing for Mutations
that Cause Autism
The extreme genetic heterogeneity of a disorder like autism
means that it is very difficult to definitively identify causa-
tive mutations in the absence of a functional assay for the
gene product. Although exome sequencing in large autism1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americcohorts has identified a multitude of de novo mutations in
candidate genes for autism, the fact that only a single or
small handful of mutations have been observed for many
of these genes has stifled attempts to discern the relevant
sequence changes from the rest. To make large-scale
screening of these genes more feasible, O’Roak et al.
tweaked a molecular-inversion-probe assay to allow rese-
quencing of a set of 44 candidate genes in a large autism
sample for a reagent cost of $1 per gene per sample. The
molecular inversion probes capture the target sequence,
which is then modified with adaptor and barcode
sequences before being pooled and sequenced. The 44
genes were sequenced in nearly 2,500 probands with
autism from the Simons Simplex Collection. The authors
uncovered 27 de novo mutations, of which six had been
missed by exome sequencing. Probabilistic modeling indi-
cated that there was a higher-than-expected mutation rate
in the 44 genes sequenced in this study. This excess muta-
tion burden was significant for six of the individual genes
as well. Although the results aren’t proof that mutations in
these genes are sufficient to cause autism, this is a more
feasible approach to sequencing the genes in large enough
cohorts to build the evidence that this is so.
O’Roak et al. (2012). Science 338, 1619–1622.
Twin Controls
Rather than focus on sequence variation in a limited
number of genes, another recent study in an autism cohort
assessed de novomutation in whole-genome sequences. In
this study by Jonathan Sebat’s and Jun Wang’s research
groups, whole-genome sequences from sets of monozy-
gotic twin pairs concordant for autism and their parents
were used for the identification of de novo germline muta-
tions. The use of twins allows true germline mutations to
be distinguished from sequence error and from mutations
that occur somatically or in the sequenced cell lines.
What the authors found actually tells us more about the
mutability of the human genome than it does about
autism. Germline mutation was distributed nonrandomly
across the genome and varied by 100-fold; it even
sometimes occurred as clusters of two or more de novo
mutations within 100 kb of each other. Certain features
of the DNA are correlated with the mutability of a region;
these include—not surprisingly—DNA sequence but also
DNase hypersensitivity, nucleosome occupancy, and
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and exons are more highly mutable, and, paradoxically,
some of the most highly conserved sequences are also
the most hypermutable. This and other recent work
together define hypermutable regions of the genome and
provide the opportunity to unravel the explanation for
this susceptibility.
Michaelson et al. (2012). Cell 151, 1431–1442.
Phenotypes in DMD Mutation Carriers
Most of what we know about Duchenne muscular
dystrophy (DMD) was discovered through observation of
affected boys. Contrary to what some believe, though, girls
who carry DMD mutations can also manifest a phenotype
that can be indistinguishable from that seen in affected
boys. On the other hand, the phenotype can be mild
to completely unrecognized. To better understand this166 The American Journal of Human Genetics 92, 165–166, Februaryclinical picture, Mercier et al. put together the largest series
of symptomaticDMD carriers to date. Although the sample
of 26 patients is biased because the researchers intention-
ally collected females who manifested symptoms before
age 17, they fall into three general phenotypic groups:
DMD, Becker-like muscular dystrophy, and early exercise
intolerance. Some of the relatively common findings in
the sample were learning issues or cognitive impairment
and cardiac dysfunction, which occurred even in child-
hood. Although the broad range of phenotype severity in
females is generally attributed to differences in patterns
of X chromosome inactivation, these patterns were skewed
in 62% of cases in this sample and did not clearly correlate
with the severity of the phenotype.
Mercier et al. (2013). Eur. J. Hum. Genet. Published online
January 9, 2013. 10.1038/ejhg.2012.269.This Month in Our Sister JournalsA Closer Link
The trait of interest in a gene-hunting study is often
some disease phenotype for which the genetic underpin-
nings are unclear. However, making the connection
between the genetic variation and the phenotype
involves a whole lot of biology, from transcription and
translation of the DNA to systems biology. Holdt et al.
reasoned that proteomic data are more directly tied to
genetic variation and that it might be fruitful to use
these data as the phenotype of interest in a quantitative
trait analysis. As proof of principle, they used F2 inter-crosses of two mouse strains and attempted quantitative
trait analysis for 176 peptides that differed in the two
parental strains (as measured by high-throughput mass
spectrometry). Of these peptides, 69 achieved significant
LOD scores. From there, the authors pursued two of the
strongest linkage signals and were able to identify the
causative genetic variation that led to differences in
two of the peptides, one for hemoglobin A and one for
Apoa2.
Holdt et al. (2012). Genetics. Published online November 19,
2012. 10.1534/genetics.112.143354.7, 2013
